Healthcare >> CEO Interviews >> October 5, 2000
DONALD R. SELLERS has served as President, Chief Executive Officer and
Director of SciClone Pharmaceuticals, Inc. since 1996. From 1993 to
present, he has also served as Managing Director of SciClone
Pharmaceuticals International Ltd. At SciClone, Mr. Sellers has helped
bring ZADAXIN', the company's leading immune system-enhancing drug, into
Phase III clinical trials in the US and Japan and into 27 countries
where it is sold worldwide, generating revenues of $14 million in 2001.
Mr. Sellers has nearly 30 years of experience in the global
pharmaceutical industry, working with SciClone, Pfizer, Revlon
Healthcare Group and Sterling Drug International. Mr. Sellers spent five
years in military intelligence, serving with Special Forces and as a
Counter-Intelligence Special Agent. He has an AB degree from Lafayette
College and a Master of International Management degree with honors from
the American Graduate School of International Management. Mr. Sellers
speaks five languages. Profile
company stands at this point?
Mr. Sellers: SciClone is about to begin Phase III pivotal studies for
the use of ZADAXIN, our
